A Phase III Study to Evaluate the Efficacy and Safety of Fruquitinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 05 Sep 2018
At a glance
- Drugs Fruquintinib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms FRUTIGA
- Sponsors Hutchison MediPharma
- 05 Sep 2018 According to a Chi-Med media release, an interim analysis to establish proof-of-concept (POC) is anticipated during the first half of 2019, and if successful could trigger a POC milestone from Lilly.
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2018 According to a Chi-Med media release, an interim analysis from this study is intended in 2019.